Neutral
UniSuper Management Pty Ltd significantly reduced its stake in Boston Scientific Corporation by 29.5% in the fourth quarter, selling 318,658 shares an...
Neutral
Boston Scientific's stock has dropped to a 52-week low of $47.16, marking a 51% decline over the past year and 47% in the last six months. Despite thi...
Neutral
Boston Scientific (BSX) has experienced a significant de-rating in 2026, with share prices down nearly 50%, despite most analysts maintaining bullish ...
Neutral
Boston Scientific (BSX) is identified as one of the best healthcare stocks with high upside potential, despite recent price target cuts by TD Cowen an...
Bearish
Truist Securities has lowered its price target for Boston Scientific Corp. (NYSE:BSX) to $64 from $85, while maintaining a Buy rating, due to a slowdo...
Bullish
Boston Scientific is investing $1.5 billion in MiRus, a Marietta-based heart-valve startup, a year after exiting the heart valve replacement market. T...
Bearish
Wolfe Research downgraded Boston Scientific Corporation (BSX) from Outperform to Peer Perform, ending a four-year bullish outlook. This decision follo...
Neutral
Canaccord has lowered its price target for Boston Scientific (NYSE:BSX) from $71 to $70, while maintaining a Buy rating, due to anticipated slowdowns ...
Bullish
Unusual options activity in Boston Scientific (BSX) suggests it could be a significant merger and acquisition (M&A) target, especially after a recent ...
Neutral
Boston Scientific has made a significant $1.5 billion investment, signaling a major move into the heart valve market. This action indicates a direct c...
Bearish
Boston Scientific's shares fell by approximately 10% to a 52-week low on Wednesday morning. This decline followed the MedTech company's announcement o...
Neutral
Boston Scientific's stock fell over 6% after the company lowered its full-year organic growth guidance to 6.5% to 8%, citing a decline in standalone W...
Bullish
Boston Scientific Corp. (US10117L1017) reported a strong Q1 2026 with an earnings beat and raised guidance, maintaining investor interest. The stock i...
Neutral
HighTower Advisors LLC reduced its position in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 5.5% during the fourth quarter, acc...
Neutral
ProShare Advisors LLC grew its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 9.3% in the fourth quarter, according to its most...
Bullish
Boston Scientific has invested $1.5 billion in MiRus LLC for an approximately 34% equity stake, securing an exclusive option to acquire the MiRus TAVR...
Neutral
Baird has reiterated an Outperform rating on Boston Scientific (BSX) but lowered its price target to $75 from $78, following the company's re-entry in...
Bullish
Boston Scientific Corp. remains a significant player in the medical technology sector, focusing on minimally invasive cardiovascular and interventiona...
Bullish
Boston Scientific's FRACTURE IDE trial for its SEISMIQ 4CE Coronary IVL Catheter met its primary safety and effectiveness endpoints, showing 93.3% fre...
Bullish
Boston Scientific Corp (BSX) shares rose 2.1% in premarket trading after the company announced a $2 billion accelerated share repurchase agreement. Th...